Qiming Venture Partners

Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America.

Shanghai Biotree biotech Co., Ltd. engages in the development of life science research technology application. The company application is used for sample testing, big data analysis, and technical product development in the field of life sciences, as well as to provides professional services. It serves universities, research institutes, hospitals, and enterprises. The company was founded in 2013 and is based in Shanghai, China.

Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

IntoCare is a high-tech company focused on the development of advanced medical devices for surgical procedures. The company specializes in powered surgical staplers, offering both reusable and disposable stapler handles. IntoCare aims to enhance surgical practices by providing reliable, intelligent, and user-friendly instruments. Through its research and development efforts, the company seeks to advance the field of surgical technology and support the marketing of nonpharmaceutical interventions, ensuring that healthcare professionals have access to innovative tools that improve patient outcomes.

Beijing Health Biotech Co. Ltd. develops diagnostic and therapeutic products for diagnosis, treatment, and monitoring of Alzheimer's disease. The company offers diagnostic and therapeutic products, such as vitamins detection, Alzheimer's disease detection and treatment, prostate AA detection, ceramides test, therapeutic drug monitoring, and screening of neonatal genetic metabolic diseases for Alzheimer's disease, cardiovascular disease, urinary disease, genetic metabolic disease, therapeutic drug monitoring, metabolite detection, steroid hormone detection, trace element quantitative detection, vitamin family detection, and microbiological identification. It also offers clinical testing and research services. The company was founded in 2016 and is based in Beijing, China.

Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

Basecamp Bio is a cell and gene therapy research and development company that develops cell and gene therapies, regenerative medicine, and immunotherapies.

Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

IntoCare is a high-tech company focused on the development of advanced medical devices for surgical procedures. The company specializes in powered surgical staplers, offering both reusable and disposable stapler handles. IntoCare aims to enhance surgical practices by providing reliable, intelligent, and user-friendly instruments. Through its research and development efforts, the company seeks to advance the field of surgical technology and support the marketing of nonpharmaceutical interventions, ensuring that healthcare professionals have access to innovative tools that improve patient outcomes.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Shanghai Biren Intelligent Technology Co., Ltd. specializes in the design and manufacture of intelligent chips, focusing on advanced computing solutions. The company operates in both software and hardware sectors, bringing together top industry talents, including technical experts and elite engineers, to develop innovative products. Its hardware division is dedicated to creating versatile computing solutions, while the software department enhances these offerings with specialized applications. Additionally, the company maintains a research institute that investigates key technologies related to intelligent computing systems, emphasizing the development of new architectures and advanced compilation techniques. Through these efforts, Biren Technology aims to establish itself as a leading player in the high-tech sector.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Bioscience integrates R&D, manufacture, marketing and provides related technical supports for IVD instruments and reagents.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

IntoCare is a high-tech company focused on the development of advanced medical devices for surgical procedures. The company specializes in powered surgical staplers, offering both reusable and disposable stapler handles. IntoCare aims to enhance surgical practices by providing reliable, intelligent, and user-friendly instruments. Through its research and development efforts, the company seeks to advance the field of surgical technology and support the marketing of nonpharmaceutical interventions, ensuring that healthcare professionals have access to innovative tools that improve patient outcomes.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

IntoCare is a high-tech company focused on the development of advanced medical devices for surgical procedures. The company specializes in powered surgical staplers, offering both reusable and disposable stapler handles. IntoCare aims to enhance surgical practices by providing reliable, intelligent, and user-friendly instruments. Through its research and development efforts, the company seeks to advance the field of surgical technology and support the marketing of nonpharmaceutical interventions, ensuring that healthcare professionals have access to innovative tools that improve patient outcomes.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Frontage Laboratories is a contract research organization that offers a comprehensive range of research, analytical, and development services to pharmaceutical, biotechnology, and agrochemical companies. The firm specializes in drug discovery and development, providing services in areas such as drug metabolism, pharmacokinetics, safety and toxicology, bioanalytical testing, and chemistry, manufacturing, and controls. Additionally, Frontage supports clinical studies through early-stage clinical services and biometrics. The company serves clients globally, with operations in the United States, Canada, China, Europe, India, Japan, Korea, Israel, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Laboratories is a subsidiary of Hong Kong Tigermed Co., Limited.

Bioscience integrates R&D, manufacture, marketing and provides related technical supports for IVD instruments and reagents.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. is an integrated pharmaceutical group based in Beijing, China, with an additional office in Haikou. Established in 2005, the company specializes in the development and production of both generic and patented therapies, as well as diagnostic agents. Sinotau offers a diverse range of products, including radiopharmaceuticals and biopharmaceuticals, and manufactures various forms of medications such as tablets, capsules, and granules for conditions affecting the cardiovascular, digestive, and respiratory systems, among others. The company's expertise in medicinal chemical synthesis, generic drug analysis, and pharmaceutical preparations is supported by advanced monoclonal antibody technologies, aiming to serve the biotechnology industry effectively.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Sinocelltech Group Limited is a Beijing-based biotech company specializing in the development and manufacture of recombinant proteins, monoclonal antibodies, and vaccines. The company has established advanced platforms for protein expression vectors, cell line development, and serum-free medium development, alongside techniques for controlled fed-batch cell culture, process scale-up, and protein purification. Sinocelltech is committed to making life-saving biological medicines accessible to the general public by continuously enhancing its manufacturing processes and technologies to reduce development and production costs.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

IntoCare is a high-tech company focused on the development of advanced medical devices for surgical procedures. The company specializes in powered surgical staplers, offering both reusable and disposable stapler handles. IntoCare aims to enhance surgical practices by providing reliable, intelligent, and user-friendly instruments. Through its research and development efforts, the company seeks to advance the field of surgical technology and support the marketing of nonpharmaceutical interventions, ensuring that healthcare professionals have access to innovative tools that improve patient outcomes.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

MedSci provides strategies, solutions and services to pharmaceutical, biotech and medical device organization and the consumer healthcare industry

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

BBI Life Sciences Corporation is one of the leading providers with the widest portfolio coverage in the life sciences research products and services industry in China. Their comprehensive product and service portfolio for life sciences research has an extensive range of applications, including (i) DNA synthesis products, (ii) genetic engineering services, (iii) life sciences research consumables; and (iv) protein and antibody related products and services. Their customers include colleges and universities, research institutes, hospitals, pharmaceutical and biotech companies, government testing and diagnostic centres, as well as distribution companies in China and overseas. Moreover, their Sangon and BBI brands have become highly recognisable in the market based on product and service quality, price competitiveness, and express delivery services. In terms of revenue in 2013, they are the largest provider of DNA synthesis products in China, and also ranked first among oligonucleotide synthesis product providers as a sub-segment of DNA synthesis products.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Goodwill Infotech provides clinical information.